BFRA - Biofrontera: A Small European Biotech With Interesting Value Proposition
Biofrontera AG (BFRA) is a small-cap German pharmaceutical company cementing its place in the photodynamic therapy market. It has an approved product Ameluz that has been on the EU market since 2012 and the USA market since October 2016. Ameluz is a prescription medication to treat non-melanoma skin cancer and its preliminary stages. The U.S. FDA has approved Ameluz for treatment of lesion and field-directed Actinic keratosis (‘AK). The product contributed €14.894M from the US market to the company’s total revenues of €21.107M in FY-2018. The company also recently acquired a US company